Literature DB >> 26727457

Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.

A F Marsman1, E L Kneepkens1, J Ruwaard1, J C Wei2, M T Nurmohamed1,3, C van Denderen1, I E van der Horst-Bruinsma1,3, T Rispens4, G Wolbink1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26727457     DOI： 10.3109/03009742.2015.1114666

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  4 in total

Review 1.  Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.

Authors:  Charlotte Krieckaert; Borja Hernández-Breijo; Johanna Elin Gehin; Guillaume le Mélédo; Alejandro Balsa; Meghna Jani; Denis Mulleman; Victoria Navarro-Compan; Gertjan Wolbink; John Isaac; Astrid van Tubergen
Journal:  RMD Open       Date:  2022-06

2.  Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.

Authors:  Jordi Gratacós; Caridad Pontes; Xavier Juanola; Jesús Sanz; Ferran Torres; Cristina Avendaño; Antoni Vallano; Gonzalo Calvo; Eugenio de Miguel; Raimon Sanmartí
Journal:  Arthritis Res Ther       Date:  2019-01-08       Impact factor: 5.156

3.  Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.

Authors:  Xiaoliang Ding; Ruifang Zhu; Jian Wu; Ling Xue; Meihua Gu; Liyan Miao
Journal:  Clin Transl Sci       Date:  2020-02-13       Impact factor: 4.689

4.  Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.

Authors:  Johanna Elin Gehin; Guro Løvik Goll; David John Warren; Silje Watterdal Syversen; Joseph Sexton; Eldri Kveine Strand; Tore Kristian Kvien; Nils Bolstad; Elisabeth Lie
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.